Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

First Page		Document Content
Date: 2014-05-12 19:51:02 Histopathology End point of clinical trials Response Evaluation Criteria in Solid Tumors Vismodegib Medicine Basal-cell carcinoma Carcinoma		Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6 Add to Reading List Source URL: www.curis.com Download Document from Source Website File Size: 321,96 KB Share Document on Facebook

	Sercrisma International S.L. HISTOLOGY AND HISTOPATHOLOGY C/Lorenzo Pausa 3, 4ºBMURCIA- Spain Fax: DocID: 1vmZg - View Document
	Histopathology 2007, 50, 113–130. DOI: j02549.x REVIEW Classification of colorectal cancer based on correlation of clinical, morphological and molecular features DocID: 1vkot - View Document
	Histology and Histopathology Histol Histopathol: http://www.hh.um.es DocID: 1vkm1 - View Document
	Appendix: Histopathology Code --a/a a/c abt aca DocID: 1uE5M - View Document
	conferenceseries.com 2nd International Conference on Cytopathology & Histopathology August 10-12, 2016 Las Vegas, USA DocID: 1tT7V - View Document